Collard and cauliflower as a base for production of recombinant antigens

Collard and cauliflower as a base for production of recombinant antigens
复制标题

DOI:
10.1016/j.plantsci.2006.06.017
复制
发表时间:
2006-07-25
期刊:
影响因子:
5.2
通讯作者:
Golovkin M
Golovkin M
中科院分区:
生物学2区
文献类型:
--
作者:
Pogrebnyak N;Markley K;Smirnov Y;Brodzik R;Bandurska K;Koprowski H;Golovkin M

文献摘要

参考文献

被引文献

相似文献

植物已成为生产重组蛋白(可用作亚单位疫苗的抗原)的现代生产系统。用于此目的的理想植物候选者应该能够维持外源蛋白的高水平表达,而不对其生长和发育产生不利影响。还重要的是其生物量大、可食用、适合长期储存和运输。这项工作是利用转基因蔬菜羽衣甘蓝和花椰菜开发基于十字花科植物的生产系统的一部分。测试并优化了几个参数,以利用含有已知病毒抗原表达盒的构建体实现这些顽固物种的有效稳定转化。使用原始程序,我们获得了转基因羽衣甘蓝变种 Morris Heading,其在叶子中表达高水平的天花候选疫苗 (B5) 并保留其正常表型。转基因花椰菜品种 Early Snowball 是通过类似的程序获得的,并且在成熟花球的小花组织中显示出可检测到的 SARS 冠状病毒刺突蛋白(SARS-CoV S1)。据我们所知,这是有史以来第一份关于转基因羽衣甘蓝植物产生的报告,也是利用这些蔬菜生产药用蛋白质的首次成功尝试。
Plants have emerged as a modern production system to produce recombinant proteins—antigens that can be used as subunit vaccines. The ideal plant candidate for this purpose should be capable to sustain high levels of expression of foreign proteins without adverse effects on its growth and development. It is also essential that it has large biomass, is edible and suitable for long-term storage and delivery. This work is a part of an effort to develop Cruciferae-based production system using transgenic vegetable plants collard and cauliflower. Several parameters were tested and optimized to achieve an efficient stable transformation of these recalcitrant species with constructs containing expression cassettes for the known viral antigens. Using the original procedure we obtained transgenic collard cv Morris Heading that express high levels of smallpox vaccine candidate (B5) in leaves and retain its normal phenotype. Transgenic cauliflower plants cv Early Snowball were obtained in similar procedure and have shown detectable amounts of SARS coronavirus spike-protein (SARS-CoV S1) in floret tissue of mature curd. To our knowledge, this is the first report on generation of transgenic collard plants ever and the first successful attempt to use these vegetables for production of pharmaceutical proteins.
DOI: 10.1038/81132
发表时间: 2000-11-01
影响因子: 46.9
作者:
Giddings, G;Allison, G;Carter, A
通讯作者: Carter, A
DOI: 10.1096/fasebj.13.13.1796
发表时间: 1999-10-01
期刊: FASEB JOURNAL
影响因子: 4.8
作者:
Kapusta, J;Modelska, A;Legocki, AB
通讯作者: Legocki, AB
DOI: 10.1093/jn/131.10.2991
发表时间: 2002-10-01
影响因子: 4.2
作者:
Lampe, JW;Peterson, S
通讯作者: Peterson, S
DOI: 10.1016/j.vaccine.2003.11.066
发表时间: 2004-06-23
期刊: VACCINE
影响因子: 5.5
作者:
Lamphear, BJ;Jilka, JM;Streatfield, SJ
通讯作者: Streatfield, SJ
DOI: 10.1128/jvi.79.10.6260-6271.2005
发表时间: 2005-05-01
影响因子: 5.4
作者:
Aldaz-Carroll, L;Whitbeck, JC;Cohen, GH
通讯作者: Cohen, GH